Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 148 participants.
Also called NCT07667517
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 148 participants
- Registry
-
NCT07667517
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07667517. Randomized; triple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
- Condition
- Albuminuria
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Finerenone (BAY 94-8862)
- Intervention (Drug)
- Placebo
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
Record details
- Record id
cardio:ct-nct07667517- Content hash
5f17928fa172a5503493d9ff73743b759071d1cc9a19cd43b7274ebb88e24b10